Clinical trials: Antitumor Drug
Chemotherapeutic Agent Toxicity, Infection
Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment
RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Infection, Malnutrition, Musculoskeletal Complications
- Trial name
- NCT00608738
- Testing
- informational intervention, medical chart review, questionnaire administration
- Volunteers
- 750 people
- Sponsor
- Northwestern University
Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in…
- Trial name
- BRAMLIE (NCT07723703)
- Testing
- AMX-883, Posaconazole
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 54 people
- Sponsor
- Amphista Therapeutics Ltd
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Cancer
A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer
This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamic effects of a novel anti-cancer drug, EPC2407, administered to patients with advanced cancer which have not responded to or have recurred following…
- Trial name
- NCT00423410
- Testing
- EPC2407 (crinobulin)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- EpiCept Corporation
Head and Neck Cancer, Human Papilloma Virus
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV Deoxyribonucleic Acid (DNA) vaccine in combination…
- Trial name
- NCT03162224
- Testing
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- MedImmune LLC
Cancer, Chemotherapeutic Agent Toxicity
Telemonitoring Platforms and Chemotherapy-Associated Toxicity
The primary objective of this trial is to evaluate the impact of a telemonitoring platform on patient satisfaction with care amongst adult cancer patients receiving chemotherapy.
- Trial name
- DETECT (NCT06077123)
- Testing
- Contigo Application
- Where
- 2 sites in Chile
- Volunteers
- 80 people
- Sponsor
- Universidad Nacional Andres Bello
Metastatic Breast Cancer, Advanced Breast Cancer
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
The purpose of the study is to demonstrate clinical efficacy of the investigational trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or 2+ (FISH-) expressing advanced or metastatic breast…
- Trial name
- NCT00452140
- Testing
- ertumaxomab
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma
- Trial name
- NCT04579224
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 448 sites in United States
- Volunteers
- 131 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumours, Carcinoma Non-small Cell Lung
First in Human Study of AZD9592 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary…
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Trial name
- EGRET (NCT05647122)
- Testing
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU)
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Breast Cancer, Biliary Tract Carcinoma
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
- Conditions
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT05123482
- Testing
- AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib)
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca
Advanced Malignant Solid Tumors
A Study of TPD3310 in Patients With Advanced Malignant Tumors
This study is a multicenter, open phase I clinical study of dose escalation,cohort expansion study to evaluate the safety,tolerability,pharmacokinetics,pharmacodynamics, and preliminary efficacy of TPD3310 in patients…
- Trial name
- NCT07368127
- Testing
- TPD3310 injection
- Where
- China
- Volunteers
- 112 people
- Sponsor
- TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
Advanced Solid Tumor
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of…
- Trial name
- NCT06598800
- Testing
- Drug: BG-T187, Other Therapeutic Agents
- Where
- 34 sites in United States, Australia and 2 more
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
At present, the clinical studies of 5-HT3RA are aimed at nausea and vomiting induced by single-day chemotherapy, but there are many chemotherapy schemes that require multi-day administration in clinical practice.
- Trial name
- NCT04472143
- Testing
- Granisetron Transdermal Delivery System
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies.
- Trial name
- NCT02264678
- Testing
- Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 358 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin, HIV Infections
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
To determine the toxicity and effectiveness of adding sargramostim (recombinant granulocyte-macrophage colony stimulating factor; GM-CSF) to a standard chemotherapy drug combination (methotrexate, bleomycin, doxorubicin…
- Trial name
- NCT00000689
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment
Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
This study is a prospective, randomized, parallel-controlled clinical trial, with the primary objective to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to…
- Trial name
- NCT06830018
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, Standard Treatment
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH
Advanced Renal Cell Carcinoma
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
This study evaluated the safety and efficacy of SHR-8068 in combination anti-tumor drugs in the treatment of advanced renal cell carcinoma
- Trial name
- NCT07239596
- Testing
- SHR-8068；Adebrelimab ；Bevacizumab, SHR-8068 ; SHR-4610
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
This phase I/II trial studies the side effects and best dose of molibresib when given together with chemotherapy (etoposide and cisplatin) and how well they work for the treatment of NUT cancer that has spread to other places in…
- Trial name
- NCT04116359
- Testing
- Cisplatin, Etoposide, Etoposide Phosphate
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Pancreatic Neoplasms
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
The purpose of this study is to identify predictive molecular markers of response to continuous daily sunitinib at dose of 37.5 mg used in patients with poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.
- Conditions
- Neuroendocrine Tumors, Pancreatic Neoplasms, Advanced Disease, Sunitinib
- Trial name
- NET (NCT01215578)
- Testing
- Sutent
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris